Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.